Schizophrenia

Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons

This chapter (2017) reviews the effects of serotonergic psychedelics on cortical layer V pyramidal neurons.

Authors

  • Marek, G. J.

Published

Current Topics in Behavioral Neurosciences
meta Study

Abstract

Recordings made from layer V (L5) pyramidal cells of the prefrontal cortex (PFC) and neocortex in rodent slice preparations have shown that serotonin (5-hydroxytryptamine, 5-HT) and serotonergic hallucinogens induce an increase in the frequency of spontaneous excitatory postsynaptic currents (EPSCs) in the apical dendritic field by activating 5-HT2A receptors. Serotonergic hallucinogens induce late EPSCs and increase recurrent network activity when subcortical or mid-cortical regions are stimulated at low frequencies (e.g., 0.1 Hz). A range of agonists or positive allosteric modulators (PAMs) for mostly Gi/o-coupled receptors, including metabotropic glutamate2 (mGlu2), adenosine A1, or μ-opioid receptors, suppress these effects of 5-HT2A receptor stimulation. Furthermore, a range of mostly Gq/11-coupled receptors (including orexin2 [OX2]; α1-adrenergic, and mGlu5 receptors) similarly induce glutamate (Glu) release onto L5 pyramidal cells. Evidence implicates a number of brain regions in mediating these effects of serotonergic hallucinogens and Gq/11-coupled receptors including the midline and intralaminar thalamic nuclei, claustrum, and neurons in deep PFC. These effects on 5-HT2A receptors and related GPCRs appear to play a major role in the behavioral effects of serotonergic hallucinogens, such as head twitches in rodents and higher order behaviors such as rodent lever pressing on the differential-reinforcement-of-low rate 72-s (DRL 72-s) schedule. This implies that the effects of 5-HT2A receptor activation on the activity of L5 pyramidal cells may be responsible for mediating a range of behaviors linked to limbic circuitry with connectivity between the PFC, striatum, thalamus, claustrum, striatum, amygdala, and the hippocampal formation.

Available with Blossom Pro

Research Summary of 'Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons'

Introduction

Marek frames this chapter as an integration of decades of electrophysiological, pharmacological, lesion, behavioural and clinical evidence linking serotonergic hallucinogens to glutamatergic signalling in the prefrontal cortex (PFC) and neocortex. Earlier work established that LSD, mescaline and psilocybin share potent agonism at 5-HT2A receptors and that activation of these receptors can produce psychotomimetic effects. Over time, however, it became clear that simple 5-HT2A blockade does not fully account for the clinical picture of psychosis and that interactions with glutamate transmission, especially onto layer V (L5) pyramidal neurons, offer a richer mechanistic account relevant to perception, cognition, mood and potential therapeutics. This review sets out to synthesise findings showing that 5-HT2A receptor activation evokes glutamate (Glu) release onto the apical dendritic field of L5 pyramidal cells, producing spontaneous and late excitatory postsynaptic currents (EPSCs) and recurrent network activity. Marek aims to connect cellular and circuit-level mechanisms (including the likely involvement of midline/intralaminar thalamic nuclei, claustrum and deep PFC neurons) to behavioural readouts in rodents and to clinical observations, with attention to the modulatory roles of many G-protein-coupled receptors (GPCRs) that either enhance or suppress this Glu release.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

  • Study Type
    meta
  • Journal
  • Topic
  • APA Citation

    Marek, G. J. (2017). Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons. Current Topics in Behavioral Neurosciences, 107-135. https://doi.org/10.1007/7854_2017_480

References (2)

Papers cited by this study that are also in Blossom

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Cited By (17)

Papers in Blossom that reference this study

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial

Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)

10 cited
The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression

Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)

Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)

Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

71 cited
Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States

Avram, M., Rogg, H., Korda, A. et al. · Frontiers in Psychiatry (2021)

35 cited
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action

Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)

Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice

Thomas, C. W., Blanco-Duque, C., Breant, B. et al. · Translational Psychiatry (2021)

Psychedelic Medicines in Major Depression: Progress and Future Challenges

Bouso, J. C., Ona, G., Dos Santos, R. G. et al. · Advances in Experimental Medicine and Biology (2021)

Show all 17 papers
The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants

Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial

Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Interactions of hallucinogens with the... — Research Summary & Context | Blossom